ArticleFrontiers in oncology2026
Synergistic antitumor efficacy of a decorin-carrying oncolytic adenovirus combined with chemotherapy in pancreatic cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in gene engineering technology have led to the increasing clinical application of oncolytic adenovirus-targeted cancer therapy. Previous studies have demonstrated that oncolytic adenoviruses carrying decorin exhibit significant efficacy in inhibiting the growth of solid tumors. Additionally, these viruses have been shown to participate in the assembly of the tumor extracellular matrix (ECM) by expressing decorin in a subcutaneous renal cell carcinoma tumor model, thereby improving the tumor immune microenvironment. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths worldwide, characterized by its insidious onset, limited treatment options, and poor long-term survival rates. The matrix surrounding pancreatic tumors is believed to be a key mediator of disease progression through its direct effects on cancer cells and indirect effects on the tumor immune microenvironment. In this study, we constructed a subcutaneous tumor model of pancreatic cancer and applied a combination of Decorin-carrying oncolytic adenoviruses and chemotherapy for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.